Please assess the completion status of the following clinical trial:

Trial Title: Attenuating The Post-Operative Insulin Resistance And Promoting Protein Anabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Elective open anatomic lung resections: segmentectomy, lobectomy, bi-lobectomy~2. Colorectal surgery for non-metastatic disease (including right, transverse, left, sigmoid, subtotal, total, and hemicolectomy)~3. Primary or secondary lung cancer~4. At least 18 years of age with~5. HbA1c 5.7- 6.5 %~6. Not receiving any kind of glucose lowering medication.~Exclusion Criteria:~1. Already diagnosed with diabetes (Hb A1c \> 6.5%)~2. Are pre-diabetic receiving glucose lowering intervention ( any glucose lowering medication)~3. Have renal or liver dysfunction (serum creatinine above 124 micromol/L in women and 133 micromol/L in men, bilirubin \>50 micromol/L)~4. will undergo extended resection of adjacent organs, chest wall resections, bronchoplasty, non-anatomic lung resections~5. Will undergo Pneumonectomy~6. Non-elective operations~7. Have mental conditions (e.g. dementia, disabling orthopedic and neuromuscular disease, psychosis),~8. Have cardiac abnormalities, severe end-organ disease such as cardiac failure (New York Heart Association classes III-IV), Chronic obstructive pulmonary disease(COPD), sepsis, morbid obesity (BMI \>40 kg/m2), anemia (hematocrit \< 30 %, hemoglobin \<100g/L albumin \< 25mg/dl)~9. Have received steroids for longer than 30 days~10. Have poor English or French comprehension.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: ACTIVE_COMPARATOR): Metformin will be administered as pills to be taken orally with an initial dose of 850 mg on the first day; the dose will be increased to 850 mg every 12 hours and 850mg every 8 hours respectively on the second day and then on the days to follow up to the morning of the surgery. Metformin will be discontinued on the day of surgery and will be restarted immediately after surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered exactly in the similar way to Metformin

Based on this trial design, predict the completion outcome and termination type (if applicable).